Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 brepocitinib study in adults with dermatomyositis
NL-OMON60635Phase 3Completed
- Sponsor
- Priovant Therapeutics
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Brepocitinib with Placebo (2 arms). Primary endpoint: Total Improvement Score at Week 52. Started Jun 2023; status: completed.
02
Drugs
brepocitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NL-OMON60635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60635.